JP6713000B2 - 抗腫瘍活性を有する化合物 - Google Patents
抗腫瘍活性を有する化合物 Download PDFInfo
- Publication number
- JP6713000B2 JP6713000B2 JP2017539023A JP2017539023A JP6713000B2 JP 6713000 B2 JP6713000 B2 JP 6713000B2 JP 2017539023 A JP2017539023 A JP 2017539023A JP 2017539023 A JP2017539023 A JP 2017539023A JP 6713000 B2 JP6713000 B2 JP 6713000B2
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- methyl
- oxazol
- ethoxymethyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*C(CC=C(C=C1)c2cnc[o]2)=C1N Chemical compound C*C(CC=C(C=C1)c2cnc[o]2)=C1N 0.000 description 3
- DQIUHCJLZJMQDO-UHFFFAOYSA-N Bc(cc1)ccc1-c1cnc(NC(C=C)=C)[o]1 Chemical compound Bc(cc1)ccc1-c1cnc(NC(C=C)=C)[o]1 DQIUHCJLZJMQDO-UHFFFAOYSA-N 0.000 description 1
- VZZUDQPQVJUFMN-UHFFFAOYSA-N C=[Br]c1ncc(C=O)cc1 Chemical compound C=[Br]c1ncc(C=O)cc1 VZZUDQPQVJUFMN-UHFFFAOYSA-N 0.000 description 1
- VIFNYCYWFBZWSQ-UHFFFAOYSA-N CC(C)(C)OC(c1cc(NC)c(C)cc1)=O Chemical compound CC(C)(C)OC(c1cc(NC)c(C)cc1)=O VIFNYCYWFBZWSQ-UHFFFAOYSA-N 0.000 description 1
- JZHANKFEAOAAMF-UHFFFAOYSA-N CC(C)(C)OC(c1cc([N+]([O-])=O)c(C)cc1)=O Chemical compound CC(C)(C)OC(c1cc([N+]([O-])=O)c(C)cc1)=O JZHANKFEAOAAMF-UHFFFAOYSA-N 0.000 description 1
- KYVOBKZHZSIVNV-UHFFFAOYSA-N CC(c(cc1)cnc1Br)Br Chemical compound CC(c(cc1)cnc1Br)Br KYVOBKZHZSIVNV-UHFFFAOYSA-N 0.000 description 1
- DFKADSLNMZURHK-UHFFFAOYSA-N CCOCc1cc(N/C(/SBr)=N/C)c(C)cc1 Chemical compound CCOCc1cc(N/C(/SBr)=N/C)c(C)cc1 DFKADSLNMZURHK-UHFFFAOYSA-N 0.000 description 1
- OOSOSILODXVVFZ-UHFFFAOYSA-N CCOCc1ccc(C)c(NC(N)=S)c1 Chemical compound CCOCc1ccc(C)c(NC(N)=S)c1 OOSOSILODXVVFZ-UHFFFAOYSA-N 0.000 description 1
- FKJSFKCZZIXQIP-UHFFFAOYSA-N O=C(CBr)c(cc1)ccc1Br Chemical compound O=C(CBr)c(cc1)ccc1Br FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N O=C1NCCN1 Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- OCGXAWPOUKOFAT-UHFFFAOYSA-N c1c[n](-c(cc2)ncc2-c2cnc[o]2)nc1 Chemical compound c1c[n](-c(cc2)ncc2-c2cnc[o]2)nc1 OCGXAWPOUKOFAT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15154028.3 | 2015-02-05 | ||
| EP15154028.3A EP3053920B1 (en) | 2015-02-05 | 2015-02-05 | Compounds with anti-tumoral activity |
| PCT/EP2016/052523 WO2016124747A1 (en) | 2015-02-05 | 2016-02-05 | Compounds with anti-tumoral activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504415A JP2018504415A (ja) | 2018-02-15 |
| JP2018504415A5 JP2018504415A5 (enExample) | 2019-03-07 |
| JP6713000B2 true JP6713000B2 (ja) | 2020-06-24 |
Family
ID=52450012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539023A Active JP6713000B2 (ja) | 2015-02-05 | 2016-02-05 | 抗腫瘍活性を有する化合物 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10570122B2 (enExample) |
| EP (2) | EP3053920B1 (enExample) |
| JP (1) | JP6713000B2 (enExample) |
| KR (1) | KR102544132B1 (enExample) |
| CN (1) | CN107531685B (enExample) |
| AR (1) | AR103629A1 (enExample) |
| AU (1) | AU2016214283B2 (enExample) |
| BR (1) | BR112017016883B1 (enExample) |
| CA (1) | CA2975644C (enExample) |
| CY (1) | CY1124948T1 (enExample) |
| DK (1) | DK3253749T3 (enExample) |
| ES (2) | ES2796276T3 (enExample) |
| HR (1) | HRP20220114T1 (enExample) |
| HU (1) | HUE059063T2 (enExample) |
| IL (1) | IL253779A0 (enExample) |
| LT (1) | LT3253749T (enExample) |
| MX (1) | MX377742B (enExample) |
| PL (1) | PL3253749T3 (enExample) |
| PT (1) | PT3253749T (enExample) |
| RS (1) | RS62901B1 (enExample) |
| RU (1) | RU2758259C2 (enExample) |
| TW (1) | TWI748938B (enExample) |
| WO (1) | WO2016124747A1 (enExample) |
| ZA (1) | ZA201705537B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018106643A1 (en) * | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| CN109467531A (zh) * | 2017-09-08 | 2019-03-15 | 沈阳科创化学品有限公司 | 一种取代吡啶二羧酸衍生物的制备方法 |
| CN112225733B (zh) * | 2020-11-25 | 2022-12-09 | 湖南科技大学 | 一种含1,3,4-噻二唑吡啶-2-酮衍生物的制备方法和作为抗癌药物的应用 |
| CN120813351A (zh) * | 2023-02-24 | 2025-10-17 | Ab科学有限公司 | 用于治疗具有染色体异常的髓系病症的化合物 |
| CN117720459A (zh) * | 2023-12-26 | 2024-03-19 | 江苏希迪制药有限公司 | 一种阿贝西利中间体5-[(4-乙基哌嗪-1-基)甲基]吡啶-2-胺制备工艺 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US810665A (en) * | 1905-10-10 | 1906-01-23 | Joseph Mlada | Mold for butter. |
| US1346834A (en) * | 1918-08-17 | 1920-07-20 | Charles E Mcmanus | Resilient rod |
| US3740420A (en) | 1967-11-28 | 1973-06-19 | Crown Zellerbach Corp | Pharmaceutical compositions with dimethyl sulfoxide |
| US3743727A (en) | 1970-11-16 | 1973-07-03 | Crown Zellerbach Corp | Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| CA1163561A (en) | 1979-11-06 | 1984-03-13 | Cyril Boroda | Preparation containing nitroglycerine and optionally other medicaments and preparation thereof |
| US4460372A (en) | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
| US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
| US4411893A (en) | 1981-08-14 | 1983-10-25 | Minnesota Mining And Manufacturing Company | Topical medicament preparations |
| CA1236029A (en) | 1984-05-14 | 1988-05-03 | Edmund Sandborn | Pharmaceutical solutions comprising dimethyl sulfoxide |
| US4615699A (en) | 1985-05-03 | 1986-10-07 | Alza Corporation | Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
| US5906202A (en) | 1996-11-21 | 1999-05-25 | Aradigm Corporation | Device and method for directing aerosolized mist to a specific area of the respiratory tract |
| US6448272B1 (en) * | 1998-12-07 | 2002-09-10 | Smithkline Beecham Corporation | Myt1 kinase inhibitors |
| JP4216947B2 (ja) * | 1999-05-18 | 2009-01-28 | 三井化学株式会社 | アミン化合物 |
| US8450302B2 (en) * | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| PT1525200E (pt) * | 2002-08-02 | 2008-01-10 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazóis para o tratamento de doenças |
| MXPA05012281A (es) * | 2003-05-14 | 2006-05-19 | Torreypines Therapeutics Inc | Compuestos y uso de los mismos en la modulacion beta amiloide. |
| EP1684750B1 (en) * | 2003-10-23 | 2010-04-28 | AB Science | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors |
| EP1789393A2 (en) | 2004-07-30 | 2007-05-30 | GPC Biotech AG | Pyridinylamines |
| JP2008510766A (ja) | 2004-08-27 | 2008-04-10 | ゲーペーツェー ビオテック アーゲー | ピリミジン誘導体 |
| CN101217954B (zh) * | 2005-04-04 | 2013-07-10 | Ab科学公司 | 经取代的噁唑衍生物及其作为酪氨酸激酶抑制剂的用途 |
| CA2607617A1 (en) * | 2005-05-09 | 2006-11-16 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
| JP5214096B2 (ja) * | 2005-06-17 | 2013-06-19 | 富士フイルムファインケミカルズ株式会社 | 新規なビピリジン誘導体 |
| WO2007026251A2 (en) * | 2005-07-14 | 2007-03-08 | Ab Science | Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma |
| JP5341516B2 (ja) * | 2005-09-13 | 2013-11-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ２−アニリン−４−アリール置換チアゾール誘導体 |
| GB0524436D0 (en) * | 2005-11-30 | 2006-01-11 | Novartis Ag | Organic compounds |
| EP2402318A1 (en) * | 2006-03-31 | 2012-01-04 | Novartis AG | DGAT inhibitors |
| JO3019B1 (ar) * | 2006-04-19 | 2016-09-05 | Janssen Pharmaceutica Nv | ثلاثي مستبدل 4،2،1-ثلاثي زولات |
| ES2352320T3 (es) | 2006-05-12 | 2011-02-17 | Ab Science | Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol. |
| FR2901273B1 (fr) * | 2006-05-19 | 2010-12-24 | Anaconda Pharma | Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant |
| JP2010526027A (ja) * | 2007-01-23 | 2010-07-29 | パラウ・フアルマ・ソシエダツド・アノニマ | プリン誘導体 |
| CA2677705A1 (en) * | 2007-02-22 | 2008-08-28 | Irm Llc | Thiazole derivatives as modulators of g protein-coupled receptors |
| GB0709031D0 (en) * | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| AU2009268875A1 (en) * | 2008-07-09 | 2010-01-14 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| JP2012180281A (ja) | 2009-06-29 | 2012-09-20 | Dainippon Sumitomo Pharma Co Ltd | 新規オキサジアゾール誘導体 |
| ES2519565T3 (es) * | 2009-07-15 | 2014-11-07 | Janssen Pharmaceuticals Inc. | Derivados de triazol e imidazol sustituidos como moduladores de gamma secretasa |
| US8871460B2 (en) * | 2009-11-09 | 2014-10-28 | Neurogenetic Pharmaceuticals, Inc. | Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor |
| AU2011206621B2 (en) * | 2010-01-12 | 2016-04-14 | Ab Science | Thiazole and oxazole kinase inhibitors |
| GB201012105D0 (en) | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
| CA2812088A1 (en) | 2010-09-14 | 2012-03-22 | Exelixis, Inc. | Phtalazine derivatives as jak1 inhibitors |
| US20120129843A1 (en) * | 2010-11-18 | 2012-05-24 | Yan Zhang | Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation |
| US20120302569A1 (en) * | 2011-05-25 | 2012-11-29 | Paul Francis Jackson | Phenyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation |
| US8551992B2 (en) * | 2011-05-27 | 2013-10-08 | Neosome Life Sciences, LLC | Aminooxazole inhibitors of cyclin dependent kinases |
| AU2012288900B2 (en) * | 2011-07-27 | 2016-10-06 | Ab Science | Selective protein kinase inhibitors |
| KR101896035B1 (ko) * | 2011-08-23 | 2018-09-07 | 덕산네오룩스 주식회사 | 유기전기소자용 신규 화합물, 이를 이용하는 유기전기소자 및 그 단말 |
| CN103436048B (zh) * | 2013-08-08 | 2014-12-03 | 陕西师范大学 | 硫脲供体双桥链有机染料及其应用 |
| US20150045353A1 (en) * | 2013-08-09 | 2015-02-12 | Neurogenetic Pharmaceuticals, Inc. | Formulations containing gamma secretase modulators, methods for preparation and delivery thereof |
| CN106414433A (zh) * | 2014-03-24 | 2017-02-15 | Ab科学有限公司 | 作为脾酪氨酸激酶抑制剂的二氮杂螺烷酮取代的噁唑衍生物 |
| EP3144307A1 (en) * | 2015-09-18 | 2017-03-22 | AB Science | Novel oxazole derivatives that inhibit syk |
-
2015
- 2015-02-05 EP EP15154028.3A patent/EP3053920B1/en active Active
- 2015-02-05 ES ES15154028T patent/ES2796276T3/es active Active
-
2016
- 2016-02-05 DK DK16703138.4T patent/DK3253749T3/da active
- 2016-02-05 AU AU2016214283A patent/AU2016214283B2/en active Active
- 2016-02-05 HU HUE16703138A patent/HUE059063T2/hu unknown
- 2016-02-05 CN CN201680008641.9A patent/CN107531685B/zh active Active
- 2016-02-05 CA CA2975644A patent/CA2975644C/en active Active
- 2016-02-05 BR BR112017016883-9A patent/BR112017016883B1/pt active IP Right Grant
- 2016-02-05 AR ARP160100337A patent/AR103629A1/es unknown
- 2016-02-05 LT LTEPPCT/EP2016/052523T patent/LT3253749T/lt unknown
- 2016-02-05 EP EP16703138.4A patent/EP3253749B1/en active Active
- 2016-02-05 PT PT167031384T patent/PT3253749T/pt unknown
- 2016-02-05 PL PL16703138T patent/PL3253749T3/pl unknown
- 2016-02-05 US US15/548,451 patent/US10570122B2/en active Active
- 2016-02-05 RS RS20220136A patent/RS62901B1/sr unknown
- 2016-02-05 WO PCT/EP2016/052523 patent/WO2016124747A1/en not_active Ceased
- 2016-02-05 RU RU2017127484A patent/RU2758259C2/ru not_active Application Discontinuation
- 2016-02-05 KR KR1020177022077A patent/KR102544132B1/ko active Active
- 2016-02-05 MX MX2017010157A patent/MX377742B/es active IP Right Grant
- 2016-02-05 JP JP2017539023A patent/JP6713000B2/ja active Active
- 2016-02-05 ES ES16703138T patent/ES2905412T3/es active Active
- 2016-02-05 TW TW105103940A patent/TWI748938B/zh not_active IP Right Cessation
- 2016-02-05 HR HRP20220114TT patent/HRP20220114T1/hr unknown
-
2017
- 2017-08-01 IL IL253779A patent/IL253779A0/en active IP Right Grant
- 2017-08-15 ZA ZA201705537A patent/ZA201705537B/en unknown
-
2022
- 2022-02-02 CY CY20221100089T patent/CY1124948T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7390415B2 (ja) | ニューロキニン－１受容体アンタゴニストとしての化合物およびその使用 | |
| CA2901022C (en) | Substituted pyridine compounds as inhibitors of histone demethylases | |
| US10105359B2 (en) | Tetrahydroisoquinoline derivatives | |
| JP6713000B2 (ja) | 抗腫瘍活性を有する化合物 | |
| JP5944503B2 (ja) | 選択的プロテインキナーゼ阻害剤 | |
| CA2973773C (en) | 2-phenyl-3h-imidazo[4,5-b]pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ror1 activity | |
| CN105073738A (zh) | 作为钠通道调节剂的喹啉及喹唑啉酰胺类 | |
| AU2018200982A1 (en) | Inhibitors of histone demethylases | |
| JP2018504415A5 (enExample) | ||
| BR112019022553A2 (pt) | novo derivado de tetrahidronaftil ureia | |
| JP2021512955A (ja) | 選択的エストロゲン受容体分解剤としての置換ベンゾチオフェン類似体 | |
| US20180202388A1 (en) | Piston for an internal combustion engine and method for producing the piston for an internal combustion engine | |
| CN118434417A (zh) | 环状磺酰胺核糖核苷酸还原酶(rnr)抑制剂及其用途 | |
| JP2017506239A (ja) | オレキシン受容体拮抗薬としての置換シクロペンタン、テトラヒドロフラン、及びピロリジン | |
| CA2943316A1 (en) | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors | |
| HK1225031A1 (en) | Compounds with anti-tumoral activity | |
| HK1225031A (en) | Compounds with anti-tumoral activity | |
| HK1243700B (en) | Compounds with anti-tumoral activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190123 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191003 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191029 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200227 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200512 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200602 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6713000 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |